Heart Failure with Preserved Ejection Fraction Treatment Study

Evaluating Metabolic Mechanisms of Ertugliflozin in Non-Diabetes Heart Failure with Preserved Ejection Fraction

AGE: >18 years old but < 75 years old
GENDER: All
HEALTHY PARTICIPANTS: No

TYPE: Interventional Study
CONDITION: Heart Disease

LOCATION: University Hospitals Cleveland Medical Center

Learn More About This Research Study

For more information, please contact Ann Dever at 216-286-5038 and leave a message or complete the online form below.

Study Purpose

The main purpose of this study is to investigate the effectiveness of ertugliflozin (a pill that lowers glucose levels) therapy to alter the heart’s metabolism to positively impact heart health and function in treating subjects with a type of chronic (long term) heart failure (HF) called heart failure with preserved ejection fraction (HFpEF).

Who Can Participate

Individuals between 18 and 75 years old who have not been hospitalized for heart failure within 6 months may be eligible for this study.

StudyID:

STUDY20210897